JP2017538772A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538772A5 JP2017538772A5 JP2017533502A JP2017533502A JP2017538772A5 JP 2017538772 A5 JP2017538772 A5 JP 2017538772A5 JP 2017533502 A JP2017533502 A JP 2017533502A JP 2017533502 A JP2017533502 A JP 2017533502A JP 2017538772 A5 JP2017538772 A5 JP 2017538772A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- fluoro
- ylidene
- indene
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 phosphonoalkyloxy Chemical group 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 229940002612 prodrug Drugs 0.000 claims description 12
- 239000000651 prodrug Substances 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- AFWAIGRROIRUIR-CFRMEGHHSA-N N-benzyl-2-[(3Z)-3-[(4-hydroxy-3,5-dimethoxyphenyl)methylidene]-6-methoxy-2-methylinden-1-yl]-N-methylacetamide Chemical compound C(C1=CC=CC=C1)N(C(CC1=C(/C(/C2=CC=C(C=C12)OC)=C/C1=CC(=C(C(=C1)OC)O)OC)C)=O)C AFWAIGRROIRUIR-CFRMEGHHSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims description 3
- 125000005199 aryl carbonyloxy group Chemical group 0.000 claims description 3
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- PCFFKTCMQHWBQA-UUYOSTAYSA-N 2-[(3Z)-3-[(4-hydroxy-3,5-dimethoxyphenyl)methylidene]-6-methoxy-2-methylinden-1-yl]-N-phenylacetamide Chemical compound OC1=C(C=C(\C=C/2\C(=C(C3=CC(=CC=C\23)OC)CC(=O)NC2=CC=CC=C2)C)C=C1OC)OC PCFFKTCMQHWBQA-UUYOSTAYSA-N 0.000 claims description 2
- TXUHXXCRGBDDLL-FBHDLOMBSA-N 2-[(3Z)-3-[(4-hydroxy-3,5-dimethoxyphenyl)methylidene]-6-methoxy-2-methylinden-1-yl]-N-pyridin-3-ylacetamide Chemical compound OC1=C(C=C(\C=C/2\C(=C(C3=CC(=CC=C\23)OC)CC(=O)NC=2C=NC=CC=2)C)C=C1OC)OC TXUHXXCRGBDDLL-FBHDLOMBSA-N 0.000 claims description 2
- QIGYLJLEFBKRPC-NHDPSOOVSA-N 2-[(3Z)-6-fluoro-3-[(4-hydroxy-3,5-dimethoxyphenyl)methylidene]-2-methylinden-1-yl]-N-phenylacetamide Chemical compound FC=1C=C2C(=C(/C(/C2=CC=1)=C/C1=CC(=C(C(=C1)OC)O)OC)C)CC(=O)NC1=CC=CC=C1 QIGYLJLEFBKRPC-NHDPSOOVSA-N 0.000 claims description 2
- RBHNASBMHJZBFY-MBTHVWNTSA-N 2-[4-[(Z)-[3-[2-(benzylamino)-2-oxoethyl]-5-fluoro-2-methylinden-1-ylidene]methyl]-2,6-dimethoxyphenyl]benzoic acid Chemical compound COc1cc(\C=C2\C(C)=C(CC(=O)NCc3ccccc3)c3cc(F)ccc23)cc(OC)c1-c1ccccc1C(O)=O RBHNASBMHJZBFY-MBTHVWNTSA-N 0.000 claims description 2
- NBXUWTRRDXULPY-WGARJPEWSA-N 2-[4-[(Z)-[3-[2-(benzylamino)-2-oxoethyl]-5-fluoro-2-methylinden-1-ylidene]methyl]-2,6-dimethoxyphenyl]pyridine-3-carboxylic acid Chemical compound COc1cc(\C=C2\C(C)=C(CC(=O)NCc3ccccc3)c3cc(F)ccc23)cc(OC)c1-c1ncccc1C(O)=O NBXUWTRRDXULPY-WGARJPEWSA-N 0.000 claims description 2
- NGMARNMVSIRBMW-WKIKZPBSSA-N 2-[4-[(Z)-[5-fluoro-2-methyl-3-[2-oxo-2-(pyridin-3-ylmethylamino)ethyl]inden-1-ylidene]methyl]-2,6-dimethoxyphenyl]benzoic acid Chemical compound COc1cc(\C=C2\C(C)=C(CC(=O)NCc3cccnc3)c3cc(F)ccc23)cc(OC)c1-c1ccccc1C(O)=O NGMARNMVSIRBMW-WKIKZPBSSA-N 0.000 claims description 2
- UXBOQICIICVKTQ-ROTLSHHCSA-N 2-[4-[(Z)-[5-fluoro-2-methyl-3-[2-oxo-2-(pyridin-3-ylmethylamino)ethyl]inden-1-ylidene]methyl]-2,6-dimethoxyphenyl]pyridine-3-carboxylic acid Chemical compound COc1cc(\C=C2\C(C)=C(CC(=O)NCc3cccnc3)c3cc(F)ccc23)cc(OC)c1-c1ncccc1C(O)=O UXBOQICIICVKTQ-ROTLSHHCSA-N 0.000 claims description 2
- WYGLMMWOUCXDKZ-MXAYSNPKSA-N 3-[4-[(Z)-[3-[2-(benzylamino)-2-oxoethyl]-5-fluoro-2-methylinden-1-ylidene]methyl]-2,6-dimethoxyphenyl]morpholine-4-carboxylic acid Chemical compound CC\1=C(C2=C(/C1=C\C3=CC(=C(C(=C3)OC)C4COCCN4C(=O)O)OC)C=CC(=C2)F)CC(=O)NCC5=CC=CC=C5 WYGLMMWOUCXDKZ-MXAYSNPKSA-N 0.000 claims description 2
- MTBULSBBUNXIPE-MYKKPKGFSA-N 3-[4-[(Z)-[5-fluoro-2-methyl-3-[2-oxo-2-(pyridin-3-ylmethylamino)ethyl]inden-1-ylidene]methyl]-2,6-dimethoxyphenyl]morpholine-4-carboxylic acid Chemical compound CC\1=C(C2=C(/C1=C\C3=CC(=C(C(=C3)OC)C4COCCN4C(=O)O)OC)C=CC(=C2)F)CC(=O)NCC5=CN=CC=C5 MTBULSBBUNXIPE-MYKKPKGFSA-N 0.000 claims description 2
- SVKMPMCRVTTZDX-FMCGGJTJSA-N C(C1=CC=CC=C1)N(C(CC1=C(/C(/C2=CC=C(C=C12)F)=C/C1=CC(=C(C(=C1)OC)O)OC)C)=O)C Chemical compound C(C1=CC=CC=C1)N(C(CC1=C(/C(/C2=CC=C(C=C12)F)=C/C1=CC(=C(C(=C1)OC)O)OC)C)=O)C SVKMPMCRVTTZDX-FMCGGJTJSA-N 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- 101150040459 RAS gene Proteins 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- PSJOJUFEHGAVOJ-YUMHPJSZSA-N [4-[(Z)-[3-[2-(benzylamino)-2-oxoethyl]-5-fluoro-2-methylinden-1-ylidene]methyl]-2,6-dimethoxyphenyl] 4-methylpiperazine-1-carboxylate Chemical compound CN1CCN(CC1)C(=O)OC1=C(C=C(C=C1OC)\C=C/1\C(=C(C2=CC(=CC=C\12)F)CC(=O)NCC1=CC=CC=C1)C)OC PSJOJUFEHGAVOJ-YUMHPJSZSA-N 0.000 claims description 2
- UNTJZMUWOQKHLZ-JJFYIABZSA-N [4-[(Z)-[3-[2-(benzylamino)-2-oxoethyl]-5-fluoro-2-methylinden-1-ylidene]methyl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound P(=O)(OC1=C(C=C(C=C1OC)\C=C/1\C(=C(C2=CC(=CC=C\12)F)CC(=O)NCC1=CC=CC=C1)C)OC)(O)O UNTJZMUWOQKHLZ-JJFYIABZSA-N 0.000 claims description 2
- QCBZYUZGBWSIQZ-WGARJPEWSA-N [4-[(Z)-[5-fluoro-2-methyl-3-[2-oxo-2-(pyridin-3-ylmethylamino)ethyl]inden-1-ylidene]methyl]-2,6-dimethoxyphenyl] 4-methylpiperazine-1-carboxylate Chemical compound CN1CCN(CC1)C(=O)OC1=C(C=C(C=C1OC)\C=C/1\C(=C(C2=CC(=CC=C\12)F)CC(NCC=1C=NC=CC=1)=O)C)OC QCBZYUZGBWSIQZ-WGARJPEWSA-N 0.000 claims description 2
- MTFAUHWAFJFHDY-NKVSQWTQSA-N [4-[(Z)-[5-fluoro-2-methyl-3-[2-oxo-2-(pyridin-3-ylmethylamino)ethyl]inden-1-ylidene]methyl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound P(=O)(OC1=C(C=C(C=C1OC)\C=C/1\C(=C(C2=CC(=CC=C\12)F)CC(NCC=1C=NC=CC=1)=O)C)OC)(O)O MTFAUHWAFJFHDY-NKVSQWTQSA-N 0.000 claims description 2
- AVTSZWAGYNVUHA-DICXZTSXSA-N [4-[(Z)-[5-fluoro-3-[2-(3-methoxyanilino)-2-oxoethyl]-2-methylinden-1-ylidene]methyl]-2,6-dimethoxyphenyl] 4-methylpiperazine-1-carboxylate Chemical compound CN1CCN(CC1)C(=O)OC1=C(C=C(C=C1OC)\C=C/1\C(=C(C2=CC(=CC=C\12)F)CC(=O)NC1=CC(=CC=C1)OC)C)OC AVTSZWAGYNVUHA-DICXZTSXSA-N 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 235000013877 carbamide Nutrition 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 108700042226 ras Genes Proteins 0.000 claims description 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- CJBUOVAXMPVXFB-UKWGHVSLSA-N 2-[(3Z)-6-fluoro-3-[(4-hydroxy-3,5-dimethoxyphenyl)methylidene]-2-methylinden-1-yl]-N-(furan-2-ylmethyl)acetamide Chemical compound FC=1C=C2C(=C(/C(/C2=CC=1)=C/C1=CC(=C(C(=C1)OC)O)OC)C)CC(=O)NCC=1OC=CC=1 CJBUOVAXMPVXFB-UKWGHVSLSA-N 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 21
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- MHQQLIAOAFTDTO-YSMPRRRNSA-N [4-[(Z)-[5-fluoro-2-methyl-3-[2-oxo-2-(pyridin-2-ylmethylamino)ethyl]inden-1-ylidene]methyl]-2,6-dimethoxyphenyl] 4-methylpiperazine-1-carboxylate Chemical compound CN1CCN(CC1)C(=O)OC1=C(C=C(C=C1OC)\C=C/1\C(=C(C2=CC(=CC=C\12)F)CC(NCC1=NC=CC=C1)=O)C)OC MHQQLIAOAFTDTO-YSMPRRRNSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/571,690 | 2014-12-16 | ||
| US14/571,690 US20160168108A1 (en) | 2014-12-16 | 2014-12-16 | Method of treating or preventing ras-mediated diseases |
| PCT/US2015/066154 WO2016100546A1 (en) | 2014-12-16 | 2015-12-16 | Method of treating or preventing ras-mediated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020005245A Division JP2020055882A (ja) | 2014-12-16 | 2020-01-16 | Ｒａｓ媒介性疾患を処置または予防する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538772A JP2017538772A (ja) | 2017-12-28 |
| JP2017538772A5 true JP2017538772A5 (enExample) | 2019-01-24 |
| JP6763858B2 JP6763858B2 (ja) | 2020-09-30 |
Family
ID=55077649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533502A Expired - Fee Related JP6763858B2 (ja) | 2014-12-16 | 2015-12-16 | Ｒａｓ媒介性疾患を処置または予防する方法 |
| JP2020005245A Withdrawn JP2020055882A (ja) | 2014-12-16 | 2020-01-16 | Ｒａｓ媒介性疾患を処置または予防する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020005245A Withdrawn JP2020055882A (ja) | 2014-12-16 | 2020-01-16 | Ｒａｓ媒介性疾患を処置または予防する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20160168108A1 (enExample) |
| EP (2) | EP3233071B1 (enExample) |
| JP (2) | JP6763858B2 (enExample) |
| CN (1) | CN107466232B (enExample) |
| DK (1) | DK3233071T3 (enExample) |
| ES (1) | ES2760898T3 (enExample) |
| PT (1) | PT3233071T (enExample) |
| WO (1) | WO2016100546A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9862698B2 (en) | 2014-12-16 | 2018-01-09 | Adt Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
| US20160168108A1 (en) | 2014-12-16 | 2016-06-16 | Adt Pharmaceuticals, Inc. | Method of treating or preventing ras-mediated diseases |
| US11186534B2 (en) * | 2017-03-17 | 2021-11-30 | University Of South Alabama | Derivatives of sulindac can protect normal cells against oxidative damage |
| CA3072616A1 (en) | 2017-08-31 | 2019-03-07 | Musc Foundation For Research Development | Indene derivatives and uses thereof |
| CN112020354A (zh) * | 2018-04-26 | 2020-12-01 | Adt制药有限责任公司 | 抗癌茚类、茚满类、氮杂茚类、氮杂茚满类、药物组合物和用途 |
| CN112312901B (zh) * | 2018-05-10 | 2024-05-14 | 路易斯维尔大学研究基金会有限公司 | Ras癌蛋白抑制剂及其制备方法和使用方法 |
| EA202190580A1 (ru) * | 2018-08-21 | 2021-06-25 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Системз | Композиции и способы для лечения злокачественных клеток посредством индукции цитотоксического оксидативного стресса |
| KR20230042600A (ko) | 2020-06-18 | 2023-03-28 | 레볼루션 메디슨즈, 인크. | Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법 |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| CN113289020B (zh) * | 2021-05-17 | 2023-04-18 | 福州大学 | 蛋白质二硫键异构酶小分子抑制剂及其应用 |
| TW202504599A (zh) | 2023-06-30 | 2025-02-01 | 美商必治妥美雅史谷比公司 | Kras抑制劑 |
| WO2025148858A1 (zh) * | 2024-01-08 | 2025-07-17 | 应世生物科技(南京)有限公司 | FAK抑制剂和Pan-RAS抑制剂 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7005270A (enExample) | 1969-04-29 | 1970-11-02 | ||
| US3888902A (en) | 1972-10-30 | 1975-06-10 | Merck & Co Inc | Cyano-indenyl acetic acids |
| US3642785A (en) | 1969-08-11 | 1972-02-15 | Merck & Co Inc | Indenyl-3-aliphatic amines |
| NL7200058A (enExample) | 1971-01-21 | 1972-07-25 | ||
| ATE40561T1 (de) | 1983-07-21 | 1989-02-15 | Troponwerke Gmbh & Co Kg | Antiphlogistika enthaltende thermoplastische kunststoffe. |
| US4656190A (en) | 1983-11-14 | 1987-04-07 | Merck & Co., Inc. | Indene derivatives and their use as PAF-antagonists |
| US5093356A (en) | 1990-01-16 | 1992-03-03 | Merck Frosst Canada, Inc. | Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase |
| US5401774A (en) | 1991-03-08 | 1995-03-28 | University Of Arizona | Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds |
| AU3162695A (en) | 1994-08-03 | 1996-03-04 | Asta Medica Aktiengesellschaft | Indol, indazol, pyridopyrrol and pyridopyrazol derivatives with anti-asthmatic, anti-allergic, anti-inflammatory and immunomodulating effects |
| US6121321A (en) | 1996-06-13 | 2000-09-19 | Cell Pathways, Inc. | Substituted methoxy benzylidene indenyl acetic and propionic acids for treating patients with precancerous lesions |
| US5965619A (en) | 1996-06-13 | 1999-10-12 | Cell Pathways Inc. | Method for treating patients having precancerous lesions with substituted indene derivatives |
| US6063818A (en) | 1996-06-13 | 2000-05-16 | Cell Pathways Inc. | Substituted benzylidene indenyl formamides, acetamides and propionamides |
| US6071934A (en) | 1997-03-25 | 2000-06-06 | Cell Pathways, Inc. | Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions |
| HUP9903620A3 (en) | 1997-06-12 | 2001-03-28 | Univ Arizona Tucson | Pharmaceutical compositions containing substituted benzylidene indenyl formamides, acetamide and propionamide derivatives and use of these compounds |
| CA2314339C (en) | 1997-12-12 | 2009-09-08 | Cell Pathways, Inc. | N-benzyl-3-indenylacetamide derivatives for treating neoplasia |
| US6028116A (en) | 1998-04-03 | 2000-02-22 | Cell Pathways, Inc. | Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia |
| US6649629B2 (en) | 1999-12-23 | 2003-11-18 | Nitromed, Inc. | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| EP1854804B1 (en) | 1999-12-28 | 2011-05-04 | Basell Polyolefine GmbH | Heterocyclic metallocene compounds and use thereof in catalyst systems for producing olefin polymers |
| CA2424222A1 (en) | 2000-10-02 | 2002-04-11 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US20030176316A1 (en) | 2001-08-24 | 2003-09-18 | Whitehead Clark M. | Methods for treatment of rheumatoid arthritis |
| DE10163426A1 (de) | 2001-12-21 | 2003-07-03 | Max Planck Gesellschaft | Pharmakologisch wirksame Inden-Derivate |
| US20030194750A1 (en) | 2002-04-05 | 2003-10-16 | Han Li | Methods for treatment of diseases where GSK 3-beta is desired, and methods to identify compounds usefule for that |
| US6538029B1 (en) | 2002-05-29 | 2003-03-25 | Cell Pathways | Methods for treatment of renal cell carcinoma |
| US7211598B2 (en) | 2002-06-28 | 2007-05-01 | Nitromed, Inc. | Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| JP2007534702A (ja) | 2004-04-26 | 2007-11-29 | バンダービルト・ユニバーシティ | 胃腸毒性の低い治療薬としてのインドール酢酸、及びインデン酢酸誘導体 |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| GB0525143D0 (en) | 2005-12-09 | 2006-01-18 | Novartis Ag | Organic compounds |
| CN101365461B (zh) | 2006-01-04 | 2013-07-24 | 南方研究所 | 舒林酸衍生物、其用途和其制备 |
| US20090221703A1 (en) | 2006-07-09 | 2009-09-03 | Chongxi Yu | High penetration composition and uses thereof |
| WO2008012603A1 (en) | 2006-07-26 | 2008-01-31 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of diflunisal and related compounds with very fast skin penetration rate |
| JP5759672B2 (ja) | 2006-07-09 | 2015-08-05 | テックフィールズ バイオケム カンパニー リミテッド | アスピリンの正荷電水溶性プロドラッグ |
| AU2016219617B2 (en) | 2006-07-09 | 2018-05-17 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of aspirin |
| AU2013206215C9 (en) | 2006-07-09 | 2018-03-08 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of aspirin |
| AU2013231152B2 (en) | 2006-07-18 | 2016-06-09 | Techfields Biochem Co. Ltd | Positively charged water-soluble pro-drugs of ibuprofen |
| CA2657636C (en) | 2006-07-18 | 2021-11-09 | Techfields Biochem Co. Ltd | Positively charged water soluble prodrugs of ibuprofen with very fast skin penetration rate |
| CN101500982A (zh) | 2006-07-25 | 2009-08-05 | 于崇曦 | 具有快速皮肤穿透速度的带正电荷的水溶性双氯芬酸前药 |
| CN108250090B (zh) | 2006-07-27 | 2021-08-20 | 于崇曦 | 具有快速皮肤穿透速度的带正电荷的水溶性酮洛芬及相关化合物的前药 |
| EP2049520A4 (en) | 2006-08-07 | 2011-01-05 | Ironwood Pharmaceuticals Inc | indole compounds |
| PL2049482T3 (pl) | 2006-08-08 | 2016-04-29 | Techfields Biochem Co Ltd | Dodatnio naładowane rozpuszczalne w wodzie proleki kwasów arylo- i heteroarylooctowych o bardzo dużej szybkości przenikania przez skórę |
| CN101506161B (zh) | 2006-08-15 | 2013-11-13 | 于崇曦 | 具有快速皮肤穿透速度的带正电荷的水溶性的芳基和杂芳基丙酸类前药 |
| AU2013206218B2 (en) | 2006-08-15 | 2016-06-30 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate |
| AU2014201024B2 (en) | 2006-09-03 | 2016-05-05 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate |
| EP2084132B1 (en) | 2006-09-03 | 2018-08-08 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate |
| JP5466006B2 (ja) | 2006-09-03 | 2014-04-09 | テックフィールズ バイオケム カンパニー リミテッド | 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ |
| CN101522692A (zh) | 2006-10-11 | 2009-09-02 | 于崇曦 | 具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药 |
| WO2008149181A1 (en) | 2007-06-04 | 2008-12-11 | Techfields Inc | Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses |
| CN102843909A (zh) | 2010-01-25 | 2012-12-26 | 埃南塔制药公司 | 丙型肝炎病毒抑制剂 |
| US9365528B2 (en) | 2011-04-01 | 2016-06-14 | Southern Research Institute | Derivatives of sulindac, use thereof and preparation thereof |
| KR20150085509A (ko) | 2012-09-21 | 2015-07-23 | 바질 리가스 | 염증-관련 장애, 통증 및 열, 피부 장애, 암 및 이의 전암성 질환의 치료용 조성물 |
| WO2015126462A1 (en) | 2014-02-19 | 2015-08-27 | Materia, Inc. | Preparation of surfactants via cross-metathesis |
| CA2908383A1 (en) | 2013-04-09 | 2014-10-16 | Materia, Inc. | Preparation of surfactants via cross-metathesis |
| US20160168108A1 (en) | 2014-12-16 | 2016-06-16 | Adt Pharmaceuticals, Inc. | Method of treating or preventing ras-mediated diseases |
| US9862698B2 (en) | 2014-12-16 | 2018-01-09 | Adt Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
| EP3233070A4 (en) | 2014-12-16 | 2018-08-08 | ADT Pharmaceuticals, LLC | Ras-inhibiting indenyl acetamide compounds, compositions, and uses |
| WO2017106520A1 (en) | 2015-12-16 | 2017-06-22 | Adt Pharmaceuticals, Inc. | Compounds, compositions and methods of treating cancer |
| CN112020354A (zh) | 2018-04-26 | 2020-12-01 | Adt制药有限责任公司 | 抗癌茚类、茚满类、氮杂茚类、氮杂茚满类、药物组合物和用途 |
-
2014
- 2014-12-16 US US14/571,690 patent/US20160168108A1/en not_active Abandoned
-
2015
- 2015-12-16 EP EP15821218.3A patent/EP3233071B1/en active Active
- 2015-12-16 CN CN201580076204.6A patent/CN107466232B/zh not_active Expired - Fee Related
- 2015-12-16 WO PCT/US2015/066154 patent/WO2016100546A1/en not_active Ceased
- 2015-12-16 PT PT158212183T patent/PT3233071T/pt unknown
- 2015-12-16 US US15/537,283 patent/US11104658B2/en not_active Expired - Fee Related
- 2015-12-16 DK DK15821218T patent/DK3233071T3/da active
- 2015-12-16 JP JP2017533502A patent/JP6763858B2/ja not_active Expired - Fee Related
- 2015-12-16 ES ES15821218T patent/ES2760898T3/es active Active
- 2015-12-16 EP EP19197686.9A patent/EP3666268A1/en not_active Withdrawn
-
2016
- 2016-02-29 US US15/056,202 patent/US9931315B2/en not_active Expired - Fee Related
-
2020
- 2020-01-16 JP JP2020005245A patent/JP2020055882A/ja not_active Withdrawn
- 2020-04-01 US US16/837,757 patent/US11198679B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117597327A (zh) | 药物制剂 | |
| JOP20220271A1 (ar) | مركبات دايازينو بيريميدين كمثبطات لـ her2 | |
| JP2018505169A5 (enExample) | ||
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| CN114072396A (zh) | 作为dna-pk抑制剂的喹啉和噌啉衍生物 | |
| CL2018001371A1 (es) | Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807) | |
| JP2021515033A5 (enExample) | ||
| CA2936551A1 (en) | Substituted pyrrolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases | |
| JP2011057693A5 (enExample) | ||
| JP2012530779A5 (enExample) | ||
| RU2018106453A (ru) | Соединения | |
| JP2012501313A5 (enExample) | ||
| JP2017511339A5 (enExample) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2018524390A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2014502972A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2015522551A5 (enExample) | ||
| SI3125888T1 (en) | 2,4-TIAZOLIDINDION DERIVATIVES FOR TREATMENT OF CENTRAL STYLE SYSTEM DISEASE | |
| JP2005538099A5 (enExample) | ||
| FI4393545T3 (fi) | Piperidinyl-indoli-johdannaisten uudet käyttötavat | |
| NZ598758A (en) | N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer | |
| EA016687B8 (ru) | Производные циклопропиламида | |
| JP2010532383A5 (enExample) |